Clareo Health | A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Shanghai Junshi Bioscience Co., Ltd.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Only the patients meeting all the following criteria can be eligible to participate in the trial:
Histologically and/or cytologically confirmed advanced or recurrent non-small cell lung cancer with EGFR sensitive mutation (exon 19 deletion, exon 21 L858R), and meeting the following conditions at the same time:
Previous first-line EGFR-TKI monotherapy with clinical benefit, followed by progression of disease;
No exon 20 T790M mutation after failure of EGFR-TKI therapy;
At least one measurable lesion (in accordance with RECIST 1.1);
You may not be if
Patients who fulfill any of the following criteria must be excluded from the study:
Histologically or cytopathologically confirmed combined with small cell lung cancer component or squamous cell carcinoma component \>10%;
Combined with other driver gene mutation with known drug therapy, including but not limited to ALK rearrangement, ROS1 mutation, BRAF600E mutation etc.;
Previous systemic chemotherapy for advanced NSCLC;
EGFR-TKI therapy within two weeks prior to enrollment;
